April 20, 2018

Update: CDI Receives MDEL In Canada for Non-Invasive Diagnostic Breath Tests for Patients with Small Intestinal Bacterial Overgrowth and Other Functional Gastrointestinal Disorders

Salem, Mass. April 20, 2018 – Commonwealth Diagnostics International, Inc. (CDI), the leader in hydrogen and methane breath testing® for functional gastrointestinal disorders, announces its entry into the Canadian healthcare market. CDI will offer its state-of-the-art, non-invasive, functional GI diagnostic tests to the approximately five million Canadians afflicted with Irritable Bowel Syndrome (IBS)\(^1\), and millions of other patients suffering from functional gastrointestinal disorders such as Small Intestinal Bacterial Overgrowth (SIBO) and carbohydrate malabsorption disorders. This announcement comes following CDI’s attainment of a Medical Device Establishment License (MDEL) from Health Canada, and in conjunction with a sponsored webinar hosted by a Canadian dietitian which was attended by more than 400 Canadian healthcare providers.

The growing body of research regarding whole-body health impacts of SIBO, as well as the recent publication of the North American Consensus on Breath Testing \(^2\), a cooperative publication by 17 world-leading clinician-scientists which identifies industry-leading protocols for using hydrogen breath testing to diagnose SIBO, represent a growing shift toward early detection of SIBO with patient-friendly, non-invasive diagnostic breath tests, saving both time and resources for patients and providers.

SIBO is the accumulation of excessive amounts of bacteria in the small intestine characterized by at least 100,000 bacteria per mL of fluid. SIBO harms both the structure and function of the small bowel. It may significantly interfere with digestion of food and absorption of nutrients, primarily by damaging the cells lining the small bowel. The main symptoms of SIBO include bloating, abdominal pain, diarrhea and/or constipation, and flatulence.

CDI’s entry into Canada improves the options available to both patients who are suffering from gastrointestinal disorders and healthcare providers challenged with diagnosing, managing, and treating the patients’ conditions. CDI’s easy-to-use diagnostic products can be used by patients in the comfort of their own home and results are delivered 24 hours after specimens are received at our CLIA-certified laboratory for analysis. We welcome patients and providers in Canada to experience the CDI difference!

To learn more about CDI, please visit our website at www.CommDx.com, or contact customer at 888-258-5966.

---
